Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 196 articles: HTML format

Single Articles

March 2021
1. ERLINGE D, Maehara A, Ben-Yehuda O, Botker HE, et al
   Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study.
   Lancet. 2021;397:985-995.
   PubMed     Abstract available
   
   
   February 2021
2. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
   Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
   Lancet. 2021;397:581-591.
   PubMed     Abstract available
   
   
   January 2021
3. KAURA A, Sterne JAC, Trickey A, Mayet J, et al
   Managing NSTEMI in older patients - Authors' reply.
   Lancet. 2021;397:371-372.
   PubMed    
   
   
   
4. CORDERO A, Rodriguez-Manero M, Bertomeu-Gonzalez V, Gonzalez-Juanatey JR, et al
   Managing NSTEMI in older patients.
   Lancet. 2021;397:370-371.
   PubMed    
   
   
   
5. VERSACI F, Frati G, Biondi-Zoccai G
   Managing NSTEMI in older patients.
   Lancet. 2021;397:370.
   PubMed    
   
   
   
6. D'ASCENZO F, De Filippo O, Gallone G, Mittone G, et al
   Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.
   Lancet. 2021;397:199-207.
   PubMed     Abstract available
   
   
   
7. TEMPLIN C, Di Vece D
   Risk scores in predicting adverse events following acute coronary syndrome.
   Lancet. 2021;397:172-173.
   PubMed    
   
   
   December 2020
8. JACKSON R, Wells S, Rodgers A
   Cardiovascular preventive strategies are not conflicting.
   Lancet. 2020;396:1879-1880.
   PubMed    
   
   
   November 2020
9. RAAL FJ, Mohamed F
   Never too old to benefit from lipid-lowering treatment.
   Lancet. 2020;396:1608-1609.
   PubMed    
   
   
   
10. GENCER B, Marston NA, Im K, Cannon CP, et al
    Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Lancet. 2020;396:1637-1643.
    PubMed     Abstract available
    
    
    
11. SILVAIN J, Lattuca B, Beygui F, Range G, et al
    Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32236.
    PubMed     Abstract available
    
    
    
12. MORTENSEN MB, Nordestgaard BG
    Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort.
    Lancet. 2020 Nov 9. pii: S0140-6736(20)32233.
    PubMed     Abstract available
    
    
    
13. MACKENZIE IS, Ford I, Nuki G, Hallas J, et al
    Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2020 Nov 6. pii: S0140-6736(20)32234.
    PubMed     Abstract available
    
    
    October 2020
14. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
    Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32173.
    PubMed     Abstract available
    
    
    
15. TAKAHASHI K, Serruys PW, Fuster V, Farkouh ME, et al
    Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNT
    Lancet. 2020 Oct 8. pii: S0140-6736(20)32114.
    PubMed     Abstract available
    
    
    
16. RAMCHAND J, Burrell LM
    Circulating ACE2: a novel biomarker of cardiovascular risk.
    Lancet. 2020;396:937-939.
    PubMed    
    
    
    September 2020
17. 
    NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    PubMed     Abstract available
    
    
    August 2020
18. KAURA A, Sterne JAC, Trickey A, Abbott S, et al
    Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data.
    Lancet. 2020;396:623-634.
    PubMed     Abstract available
    
    
    
19. BENDZ B, Aaberge L
    Acute coronary syndromes in older patients: does older age matter?
    Lancet. 2020;396:585-587.
    PubMed    
    
    
    
20. FERRARI R, Ford I, Fox K, Challeton JP, et al
    Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31790.
    PubMed     Abstract available
    
    
    
21. KIM HS, Kang J, Hwang D, Han JK, et al
    Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31791.
    PubMed     Abstract available
    
    
    
22. MACLAREN G
    In sepsis-induced heart failure, extracorporeal membrane oxygenation can provide support.
    Lancet. 2020;396:515-517.
    PubMed    
    
    
    
23. BRECHOT N, Hajage D, Kimmoun A, Demiselle J, et al
    Venoarterial extracorporeal membrane oxygenation to rescue sepsis-induced cardiogenic shock: a retrospective, multicentre, international cohort study.
    Lancet. 2020;396:545-552.
    PubMed     Abstract available
    
    
    
24. SCHWALM JD, McCready T, Islam S, McKee M, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
    Lancet. 2020;396:310-311.
    PubMed    
    
    
    
25. RICHARDS A
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:310.
    PubMed    
    
    
    
26. HENDRIKS M, van Andel J, Asiki G, Kyobutungi C, et al
    Cardiovascular risk in hypertension: open questions about HOPE 4.
    Lancet. 2020;396:309-310.
    PubMed    
    
    
    July 2020
27. COMBES A, Price S, Slutsky AS, Brodie D, et al
    Temporary circulatory support for cardiogenic shock.
    Lancet. 2020;396:199-212.
    PubMed     Abstract available
    
    
    
28. MAFHAM MM, Spata E, Goldacre R, Gair D, et al
    COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England.
    Lancet. 2020 Jul 14. pii: S0140-6736(20)31356.
    PubMed     Abstract available
    
    
    
29. CHI G, Marszalek J
    Differential effect of ticagrelor on irreversible harms in diabetes.
    Lancet. 2020;396:93.
    PubMed    
    
    
    June 2020
30. STRONGMAN H, Lyon AR, Dos Santos Silva I, Smeeth L, et al
    Cancer and cardiovascular disease - Authors' reply.
    Lancet. 2020;395:1904-1905.
    PubMed    
    
    
    
31. KNISELY JPS, Henry SA, Saba SG, Puckett LL, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1904.
    PubMed    
    
    
    
32. ALAM N, Wright AK, Ashcroft DM, Renehan AG, et al
    Cancer and cardiovascular disease.
    Lancet. 2020;395:1903-1904.
    PubMed    
    
    
    
33. 
    Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
    Lancet. 2020;395:1927-1936.
    PubMed     Abstract available
    
    
    May 2020
34. BUGIARDINI R, Cenko E
    Sex differences in myocardial infarction deaths.
    Lancet. 2020 May 20. pii: S0140-6736(20)31049.
    PubMed    
    
    
    
35. WALLI-ATTAEI M, Joseph P, Rosengren A, Chow CK, et al
    Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2020 May 20. pii: S0140-6736(20)30543.
    PubMed     Abstract available
    
    
    
36. HOLMES JL, Brake S, Docherty M, Lilford R, et al
    Emergency ambulance services for heart attack and stroke during UK's COVID-19 lockdown.
    Lancet. 2020 May 14. pii: S0140-6736(20)31031.
    PubMed    
    
    
    
37. BYRNE RA, Colleran R
    Aspirin for secondary prevention of cardiovascular disease.
    Lancet. 2020;395:1462-1463.
    PubMed    
    
    
    
38. CHIARITO M, Sanz-Sanchez J, Cannata F, Cao D, et al
    Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
    Lancet. 2020;395:1487-1495.
    PubMed     Abstract available
    
    
    April 2020
39. GIMBEL M, Qaderdan K, Willemsen L, Hermanides R, et al
    Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Lancet. 2020;395:1374-1381.
    PubMed     Abstract available
    
    
    
40. SINNAEVE PR, Gevaert SA
    Antiplatelet strategies in ageing patients with acute coronary syndromes.
    Lancet. 2020;395:1319-1321.
    PubMed    
    
    
    March 2020
41. HERRETT E, Jackson R, Smeeth L
    Managing cardiovascular disease risk in hypertension - Authors' reply.
    Lancet. 2020;395:870.
    PubMed    
    
    
    
42. MCMANUS R, Constanti M, Floyd CN, Glover M, et al
    Managing cardiovascular disease risk in hypertension.
    Lancet. 2020;395:869-870.
    PubMed    
    
    
    February 2020
43. 
    Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
    Lancet. 2020;395:698-708.
    PubMed     Abstract available
    
    
    
44. DASA O, Ruzieh M
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:414.
    PubMed    
    
    
    
45. ROSHANDEL G, Kamangar F, Marshall T, Cheng KK, et al
    Polypill for prevention of cardiovascular diseases - Authors' reply.
    Lancet. 2020;395:414-415.
    PubMed    
    
    
    
46. DIMMITT SB, Stampfer HG
    Polypill for prevention of cardiovascular diseases.
    Lancet. 2020;395:413-414.
    PubMed    
    
    
    January 2020
47. MORICE MC
    Patients with left main coronary artery disease: stent or surgery?
    Lancet. 2020;395:167-168.
    PubMed    
    
    
    December 2019
48. HOLM NR, Makikallio T, Lindsay MM, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
    Lancet. 2019 Dec 23. pii: S0140-6736(19)32972.
    PubMed     Abstract available
    
    
    
49. BRUNNER FJ, Waldeyer C, Ojeda F, Salomaa V, et al
    Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium.
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32519.
    PubMed     Abstract available
    
    
    
50. ROBINSON JG
    The next treatment paradigm in cardiovascular prevention?
    Lancet. 2019 Dec 3. pii: S0140-6736(19)32949.
    PubMed    
    
    
    October 2019
51. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    PubMed     Abstract available
    
    
    
52. VANEZIS AP
    The broken promise of remote ischaemic conditioning.
    Lancet. 2019;394:1389-1390.
    PubMed    
    
    
    
53. VON BIRGELEN C, Buiten RA
    Superiority of biodegradable polymer sirolimus-eluting stents in STEMI.
    Lancet. 2019;394:1208-1210.
    PubMed    
    
    
    September 2019
54. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available
    
    
    
55. ERLINGE D
    NIRS-intravascular imaging to predict coronary events.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)32217.
    PubMed    
    
    
    
56. WAKSMAN R, Di Mario C, Torguson R, Ali ZA, et al
    Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.
    Lancet. 2019 Sep 26. pii: S0140-6736(19)31794.
    PubMed     Abstract available
    
    
    
57. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
    Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
    PubMed     Abstract available
    
    
    
58. READ SH, Wild SH
    Prevention of premature cardiovascular death worldwide.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32034.
    PubMed    
    
    
    
59. VRANCKX P, Valgimigli M, Eckardt L, Tijssen J, et al
    Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)31872.
    PubMed     Abstract available
    
    
    
60. YUSUF S, Joseph P, Rangarajan S, Islam S, et al
    Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
    Lancet. 2019 Sep 2. pii: S0140-6736(19)32008.
    PubMed     Abstract available
    
    
    August 2019
61. IGLESIAS JF, Muller O, Heg D, Roffi M, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31877.
    PubMed     Abstract available
    
    
    
62. THUIJS DJFM, Kappetein AP, Serruys PW, Mohr FW, et al
    Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31997.
    PubMed     Abstract available
    
    
    
63. TAGGART DP, Pagano D
    Expansion or contraction of stenting in coronary artery disease?
    Lancet. 2019 Aug 30. pii: S0140-6736(19)32040.
    PubMed    
    
    
    
64. SCHWALM JD, McCready T, Lopez-Jaramillo P, Yusoff K, et al
    A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31949.
    PubMed     Abstract available
    
    
    
65. JAFAR TH, Samad Z, Bloomfield GS
    Parallel community solutions for cardiovascular risk reduction.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31995.
    PubMed    
    
    
    
66. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Abstract available
    
    
    
67. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    PubMed    
    
    
    
68. STAFF AC
    Long-term cardiovascular health after stopping pre-eclampsia.
    Lancet. 2019 Aug 28. pii: S0140-6736(19)31993.
    PubMed    
    
    
    
69. NASLUND U, Ng N, Wennberg P, Norberg M, et al
    Patient-doctor engagement in cardiovascular prevention - Authors' reply.
    Lancet. 2019;394:e27.
    PubMed    
    
    
    
70. ANYFANTI P, Gkaliagkousi E, Douma S
    Patient-doctor engagement in cardiovascular prevention.
    Lancet. 2019;394:e26.
    PubMed    
    
    
    
71. RAY KK, Corral P, Morales E, Nicholls SJ, et al
    Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options.
    Lancet. 2019;394:697-708.
    PubMed     Abstract available
    
    
    
72. GUPTA R, Wood DA
    Primary prevention of ischaemic heart disease: populations, individuals, and health professionals.
    Lancet. 2019;394:685-696.
    PubMed     Abstract available
    
    
    
73. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    PubMed     Abstract available
    
    
    
74. STRONGMAN H, Gadd S, Matthews A, Mansfield KE, et al
    Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31674.
    PubMed     Abstract available
    
    
    
75. BLAES AH, Shenoy C
    Is it time to include cancer in cardiovascular risk prediction tools?
    Lancet. 2019 Aug 20. pii: S0140-6736(19)31886.
    PubMed    
    
    
    
76. NASLUND U, Lundgren A, Vanoli D, Norberg M, et al
    Is intima-media thickness a predictor for cardiovascular risk? - Authors' reply.
    Lancet. 2019;394:381.
    PubMed    
    
    
    
77. GONZALEZ-CANTERO A, Gonzalez-Cantero J, Sanchez-Moya AI, Rodriguez-Padial L, et al
    Is intima-media thickness a predictor for cardiovascular risk?
    Lancet. 2019;394:380-381.
    PubMed    
    
    
    July 2019
78. HERRETT E, Gadd S, Jackson R, Bhaskaran K, et al
    Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
    Lancet. 2019 Jul 25. pii: S0140-6736(19)31359.
    PubMed     Abstract available
    
    
    June 2019
79. BARNETT R
    Acute myocardial infarction.
    Lancet. 2019;393:2580.
    PubMed    
    
    
    
80. TIJSSEN RYG, de Winter RJ, Wykrzykowska JJ
    ABSORB IV: will the low rate of scaffold thrombosis persist?
    Lancet. 2019;393:2392.
    PubMed    
    
    
    
81. STONE GW, Ellis SG, Kereiakes DJ
    ABSORB IV: will the low rate of scaffold thrombosis persist? - Authors' reply.
    Lancet. 2019;393:2392-2393.
    PubMed    
    
    
    
82. RISSANEN TT, Uskela S, Eranen J, Mantyla P, et al
    Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
    Lancet. 2019 Jun 13. pii: S0140-6736(19)31126.
    PubMed     Abstract available
    
    
    
83. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Abstract available
    
    
    
84. OIKONOMOU EK, Antoniades C
    Detection of coronary inflammation - Authors' reply.
    Lancet. 2019;393:2199-2200.
    PubMed    
    
    
    May 2019
85. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Abstract available
    
    
    
86. FUDIM M, Ali-Ahmed F, Patel MR, Sobotka PA, et al
    Sham trials: benefits and risks for cardiovascular research and patients.
    Lancet. 2019;393:2104-2106.
    PubMed    
    
    
    
87. JEGER RV, Kaiser C, Gilgen N, Coslovsky M, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2 - Authors' reply.
    Lancet. 2019;393:1934-1935.
    PubMed    
    
    
    
88. SAJADIEH A, Kumarathurai P, Jeppesen JL
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1934.
    PubMed    
    
    
    
89. ALFONSO F, Guimaraes MG, Rivero F, Cuesta J, et al
    Drug-coated balloons: room for development of BASKET-SMALL 2.
    Lancet. 2019;393:1933-1934.
    PubMed    
    
    
    
90. SHAH R, Khan B
    The MATRIX trial.
    Lancet. 2019;393:1803.
    PubMed    
    
    
    
91. MEYER TM, Hollenbeck M, Kielstein JT
    The MATRIX trial.
    Lancet. 2019;393:1802-1803.
    PubMed    
    
    
    
92. PICCOLO R, Bonaa KH, Efthimiou O, Varenne O, et al
    Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
    Lancet. 2019 May 2. pii: S0140-6736(19)30474.
    PubMed     Abstract available
    
    
    
93. JENSEN LO, Christiansen EH
    Are drug-eluting stents safer than bare-metal stents?
    Lancet. 2019 May 2. pii: S0140-6736(19)31000.
    PubMed    
    
    
    April 2019
94. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed    
    
    
    
95. MILLWOOD IY, Walters RG, Mei XW, Guo Y, et al
    Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)31772.
    PubMed     Abstract available
    
    
    March 2019
96. THE LANCET EDITORS
    Retraction-Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.
    Lancet. 2019;393:1084.
    PubMed    
    
    
    
97. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed    
    
    
    
98. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed    
    
    
    
99. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed    
    
    
    
100. BAX JJ, Di Carli M, Narula J, Delgado V, et al
     Multimodality imaging in ischaemic heart failure.
     Lancet. 2019;393:1056-1070.
     PubMed     Abstract available
     
     
     
101. MCCRINDLE BW, Rowley AH
     Improving coronary artery outcomes for children with Kawasaki disease.
     Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
     PubMed    
     
     
     
102. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
     Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
     Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
     PubMed     Abstract available
     
     
     February 2019
103. KIMURA T
     Can ultra-thin strut drug-eluting stents improve outcomes?
     Lancet. 2019 Feb 28. pii: S0140-6736(19)30286.
     PubMed    
     
     
     
104. ZAMAN A, de Winter RJ, Kogame N, Chang CC, et al
     Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
     Lancet. 2019 Feb 28. pii: S0140-6736(18)32467.
     PubMed     Abstract available
     
     
     
105. MEHRAN R, Vogel B, Ortega R, Cooney R, et al
     The Lancet Commission on women and cardiovascular disease: time for a shift in women's health.
     Lancet. 2019 Feb 8. pii: S0140-6736(19)30315.
     PubMed    
     
     
     December 2018
106. NASLUND U, Ng N, Lundgren A, Fharm E, et al
     Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.
     Lancet. 2018 Dec 3. pii: S0140-6736(18)32818.
     PubMed     Abstract available
     
     
     November 2018
107. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
     SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
     Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
     PubMed     Abstract available
     
     
     October 2018
108. COLOMBO A, Giannini F
     Encouraging data from ABSORB IV pave the way to new scaffolds.
     Lancet. 2018;392:1490-1491.
     PubMed    
     
     
     
109. STONE GW, Ellis SG, Gori T, Metzger DC, et al
     Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
     Lancet. 2018;392:1530-1540.
     PubMed     Abstract available
     
     
     
110. WILLEIT P, Ridker PM, Nestel PJ, Simes J, et al
     Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
     Lancet. 2018 Oct 4. pii: S0140-6736(18)31652.
     PubMed     Abstract available
     
     
     
111. MAFHAM M, Preiss D
     HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
     Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
     PubMed    
     
     
     
112. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
     Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
     Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
     PubMed     Abstract available
     
     
     September 2018
113. CAMENZIND E, Popovic B
     Are all drug-eluting stents created equal?
     Lancet. 2018 Sep 21. pii: S0140-6736(18)32334.
     PubMed    
     
     
     
114. VON BIRGELEN C, Zocca P, Buiten RA, Jessurun GAJ, et al
     Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, ran
     Lancet. 2018 Sep 21. pii: S0140-6736(18)32001.
     PubMed     Abstract available
     
     
     
115. DEHGHAN M, Mente A, Rangarajan S, Sheridan P, et al
     Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.
     Lancet. 2018 Sep 11. pii: S0140-6736(18)31812.
     PubMed     Abstract available
     
     
     
116. HO HH, Ong PJL
     BASKET-SMALL 2: advancing DCB beyond in-stent restenosis.
     Lancet. 2018;392:802-804.
     PubMed    
     
     
     
117. LANSKY A, Wijns W, Xu B, Kelbaek H, et al
     Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.
     Lancet. 2018 Sep 3. pii: S0140-6736(18)31649.
     PubMed     Abstract available
     
     
     
118. PILGRIM T, Piccolo R, Heg D, Roffi M, et al
     Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
     Lancet. 2018;392:737-746.
     PubMed     Abstract available
     
     
     August 2018
119. VRANCKX P, Valgimigli M, Juni P, Hamm C, et al
     Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, ope
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31858.
     PubMed     Abstract available
     
     
     
120. CAPODANNO D, Angiolillo DJ
     Aspirin for primary prevention of cardiovascular disease.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31990.
     PubMed    
     
     
     
121. GAZIANO JM, Brotons C, Coppolecchia R, Cricelli C, et al
     Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31924.
     PubMed     Abstract available
     
     
     
122. VALGIMIGLI M, Frigoli E, Leonardi S, Vranckx P, et al
     Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31714.
     PubMed     Abstract available
     
     
     
123. ANGIOLILLO DJ
     Vascular access and antithrombotic therapy in patients with acute coronary syndrome.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31921.
     PubMed    
     
     
     
124. BLANKENBERG S, Neumann JT, Westermann D
     Diagnosing myocardial infarction: a highly sensitive issue.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31996.
     PubMed    
     
     
     
125. JEGER RV, Farah A, Ohlow MA, Mangner N, et al
     Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31719.
     PubMed     Abstract available
     
     
     
126. SHAH ASV, Anand A, Strachan FE, Ferry AV, et al
     High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31923.
     PubMed     Abstract available
     
     
     
127. OIKONOMOU EK, Marwan M, Desai MY, Mancio J, et al
     Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31114.
     PubMed     Abstract available
     
     
     
128. MAHABADI AA, Rassaf T
     Imaging of coronary inflammation for cardiovascular risk prediction.
     Lancet. 2018 Aug 24. pii: S0140-6736(18)31716.
     PubMed    
     
     
     
129. MENTE A, O'Donnell M, Rangarajan S, McQueen M, et al
     Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
     Lancet. 2018;392:496-506.
     PubMed     Abstract available
     
     
     
130. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
     Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
     Lancet. 2018;392:477-486.
     PubMed     Abstract available
     
     
     July 2018
131. THEKEN KN, Grosser T
     Weight-adjusted aspirin for cardiovascular prevention.
     Lancet. 2018 Jul 12. pii: S0140-6736(18)31307.
     PubMed    
     
     
     
132. DOWLING C, Firoozi S, Brecker S
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:28.
     PubMed    
     
     
     
133. FRANCIS DP, Al-Lamee R
     Percutaneous coronary intervention for stable angina in ORBITA - Authors' reply.
     Lancet. 2018;392:28-30.
     PubMed    
     
     
     
134. BANNING A, Redwood S
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:28.
     PubMed    
     
     
     
135. BAUER A, Rizas KD, Massberg S
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:27.
     PubMed    
     
     
     
136. REED GW, Kapadia SR
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:27-28.
     PubMed    
     
     
     
137. POCOCK SJ
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:26-27.
     PubMed    
     
     
     
138. BARAKAT MF, Simitsis P
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:26.
     PubMed    
     
     
     
139. TU T, Liu Q, Hu X, Zhou S, et al
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:25.
     PubMed    
     
     
     
140. MUTHALALY RG, Nerlekar N, Brown AJ
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:25-26.
     PubMed    
     
     
     
141. DEGRELL P, Picard F, Varenne O
     Percutaneous coronary intervention for stable angina in ORBITA.
     Lancet. 2018;392:25.
     PubMed    
     
     
     June 2018
142. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
     Endpoints in diabetes cardiovascular outcome trials.
     Lancet. 2018;391:2412.
     PubMed    
     
     
     
143. MARIATHAS M, Curzen N
     Troponin assays: developing indications.
     Lancet. 2018;391:2398-2399.
     PubMed    
     
     
     
144. DEVEREAUX PJ, Duceppe E, Guyatt G, Tandon V, et al
     Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
     Lancet. 2018;391:2325-2334.
     PubMed     Abstract available
     
     
     
145. IKEMURA N, Sawano M, Ueda I, Fukuda K, et al
     Consequence of reimbursement policy alteration for urgent PCI in Japan.
     Lancet. 2018;391:2208-2209.
     PubMed    
     
     
     May 2018
146. MONTAIGNE D, Coisne A, Marechal X, Lefebvre P, et al
     Daytime variations in perioperative myocardial injury - Authors' reply.
     Lancet. 2018;391:2106.
     PubMed    
     
     
     
147. SPADACCIO C, Dalby M, Danton MHD
     Daytime variations in perioperative myocardial injury.
     Lancet. 2018;391:2105-2106.
     PubMed    
     
     
     
148. LUCCHINETTI E, Zaugg M
     Daytime variations in perioperative myocardial injury.
     Lancet. 2018;391:2104-2105.
     PubMed    
     
     
     
149. BARTMAN CM, Oyama Y, Eckle T
     Daytime variations in perioperative myocardial injury.
     Lancet. 2018;391:2104.
     PubMed    
     
     
     
150. BRILAKIS ES, Edson R, Bhatt DL, Goldman S, et al
     Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
     Lancet. 2018 May 11. pii: S0140-6736(18)30801.
     PubMed     Abstract available
     
     
     
151. PYLYPCHUK R, Wells S, Kerr A, Poppe K, et al
     Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
     Lancet. 2018 May 4. pii: S0140-6736(18)30664.
     PubMed     Abstract available
     
     
     
152. DAMEN JAAG, Hooft L, Moons KGM
     Contemporary cardiovascular risk prediction.
     Lancet. 2018 May 4. pii: S0140-6736(18)30842.
     PubMed    
     
     
     April 2018
153. DEHGHAN M, Mente A, Yusuf S
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply.
     Lancet. 2018;391:1681-1682.
     PubMed    
     
     
     
154. HANSEL B, Roussel R, Giral P
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1680.
     PubMed    
     
     
     
155. KLEBER ME, Delgado GE, Dawczynski C, Lorkowski S, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1680-1681.
     PubMed    
     
     
     
156. CAO XP, Tan CC, Yu JT
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1679-1680.
     PubMed    
     
     
     
157. CARBONE S, Billingsley H, Abbate A
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1679.
     PubMed    
     
     
     
158. LORKOWSKI S, Richter M, Linseisen J, Watzl B, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1678-1679.
     PubMed    
     
     
     
159. ROSSOUW JE, Prentice RL
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1677.
     PubMed    
     
     
     
160. BHOPAL RS, Misra A
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1677-1678.
     PubMed    
     
     
     
161. MANN J, Meerpohl J, Nishida C, McLean R, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676.
     PubMed    
     
     
     
162. REYNOLDS AN
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676.
     PubMed    
     
     
     
163. KAHLEOVA H, Crosby L, Levin S, Barnard ND, et al
     Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple?
     Lancet. 2018;391:1676-1677.
     PubMed    
     
     
     
164. CHU DK, Kim LH, Young PJ, Zamiri N, et al
     Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.
     Lancet. 2018;391:1693-1705.
     PubMed     Abstract available
     
     
     March 2018
165. ALKHALIL M
     Bioresorbable polymer drug-eluting stents.
     Lancet. 2018;391:936.
     PubMed    
     
     
     
166. KANDZARI DE, Mauri L, Koolen JJ, Doros G, et al
     Bioresorbable polymer drug-eluting stents - Authors' reply.
     Lancet. 2018;391:936-937.
     PubMed    
     
     
     
167. SHAH R
     Bioresorbable polymer drug-eluting stents.
     Lancet. 2018;391:935-936.
     PubMed    
     
     
     
168. MOTOVSKA Z, Bhatt DL
     12 months of DAPT after acute coronary syndrome still beats 6 months.
     Lancet. 2018 Mar 9. pii: S0140-6736(18)30612.
     PubMed    
     
     
     
169. HAHN JY, Song YB, Oh JH, Cho DK, et al
     6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
     Lancet. 2018 Mar 9. pii: S0140-6736(18)30493.
     PubMed     Abstract available
     
     
     February 2018
170. HEAD SJ, Milojevic M, Daemen J, Ahn JM, et al
     Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
     Lancet. 2018 Feb 22. pii: S0140-6736(18)30423.
     PubMed     Abstract available
     
     
     
171. BHATT DL
     CABG the clear choice for patients with diabetes and multivessel disease.
     Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
     PubMed    
     
     
     
172. PAULES CI, Subbarao K
     Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
     Lancet. 2018;391:427-428.
     PubMed    
     
     
     
173. CALDEIRA D, Ferreira JJ, Costa J
     Influenza vaccination and prevention of cardiovascular disease mortality.
     Lancet. 2018;391:426-427.
     PubMed    
     
     
     January 2018
174. JOBS A, Desch S, Thiele H
     Great expectations - Authors' reply.
     Lancet. 2018;391:306-307.
     PubMed    
     
     
     
175. LEMESLE G, Laine M, Pankert M, Puymirat E, et al
     Great expectations.
     Lancet. 2018;391:306.
     PubMed    
     
     
     
176. ANAND SS, Bosch J, Eikelboom JW, Connolly SJ, et al
     Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
     Lancet. 2018;391:219-229.
     PubMed     Abstract available
     
     
     
177. BOCHATON T, Ovize M
     Circadian rhythm and ischaemia-reperfusion injury.
     Lancet. 2018;391:8-9.
     PubMed    
     
     
     
178. BROWN DL, Redberg RF
     Last nail in the coffin for PCI in stable angina?
     Lancet. 2018;391:3-4.
     PubMed    
     
     
     
179. GERBER RT, Gershlick AH
     A SENIOR moment? Bare-metal stents in elderly patients.
     Lancet. 2018;391:4-6.
     PubMed    
     
     
     December 2017
180. SCHUMACHER H, Mahfoud F, Bohm M
     Overestimation of cardiovascular outcome incidence - Authors' reply.
     Lancet. 2017;390:2547.
     PubMed    
     
     
     
181. YE Y, Fonseca R
     Overestimation of cardiovascular outcome incidence.
     Lancet. 2017;390:2546-2547.
     PubMed    
     
     
     
182. THURSTON GD, Newman JD
     Walking to a pathway for cardiovascular effects of air pollution.
     Lancet. 2017 Dec 5. pii: S0140-6736(17)33078.
     PubMed    
     
     
     
183. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
     Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
     Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
     PubMed     Abstract available
     
     
     
184. DE WINTER RJ, Katagiri Y, Asano T, Milewski KP, et al
     A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 tri
     Lancet. 2017 Dec 1. pii: S0140-6736(17)33103.
     PubMed     Abstract available
     
     
     November 2017
185. RIDKER PM, MacFadyen JG, Everett BM, Libby P, et al
     Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
     Lancet. 2017 Nov 13. pii: S0140-6736(17)32814.
     PubMed     Abstract available
     
     
     
186. CONNOLLY SJ, Eikelboom JW, Bosch J, Dagenais G, et al
     Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
     Lancet. 2017 Nov 10. pii: S0140-6736(17)32458.
     PubMed     Abstract available
     
     
     
187. PRABHAKARAN D, Anand S, Watkins D, Gaziano T, et al
     Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.
     Lancet. 2017 Nov 3. pii: S0140-6736(17)32471.
     PubMed     Abstract available
     
     
     
188. AL-LAMEE R, Thompson D, Dehbi HM, Sen S, et al
     Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
     Lancet. 2017 Nov 1. pii: S0140-6736(17)32714.
     PubMed     Abstract available
     
     
     October 2017
189. VARENNE O, Cook S, Sideris G, Kedev S, et al
     Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.
     Lancet. 2017 Oct 31. pii: S0140-6736(17)32713.
     PubMed     Abstract available
     
     
     
190. MONTAIGNE D, Marechal X, Modine T, Coisne A, et al
     Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbalpha antagonism: a single-centre propensity-matched cohort study and a randomised study.
     Lancet. 2017 Oct 26. pii: S0140-6736(17)32132.
     PubMed     Abstract available
     
     
     
191. BYRNE RA, Schuster T
     Biodegradable polymer drug-eluting stents: caveat emptor.
     Lancet. 2017;390:1814-1816.
     PubMed    
     
     
     September 2017
192. LEAR SA, Hu W, Rangarajan S, Gasevic D, et al
     The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.
     Lancet. 2017 Sep 21. pii: S0140-6736(17)31634.
     PubMed     Abstract available
     
     
     August 2017
193. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
     Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
     Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
     PubMed     Abstract available
     
     
     
194. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
     Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
     Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
     PubMed     Abstract available
     
     
     
195. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
     Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
     Lancet. 2017;390:747-759.
     PubMed     Abstract available
     
     
     April 2017
196. SHAH R
     Optical coherence tomography-guided PCI.
     Lancet. 2017;389:1607.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: